search
Back to results

Method of Genetic Analysis in Genodermatoses (GENODERM)

Primary Purpose

Genodermatosis, Rare Genetic Disease With Cutaneous Expression

Status
Unknown status
Phase
Not Applicable
Locations
Belgium
Study Type
Interventional
Intervention
Genetic diagnostic by mendeliome or genome
Sponsored by
Queen Fabiola Children's University Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Genodermatosis focused on measuring Genodermatosis, genetic, children

Eligibility Criteria

undefined - 18 Years (Child, Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Children between 0 to 18 years old
  • Presence of dermatological symptoms suggesting genodermatosis
  • Presence of systemic symptoms in an undiagnosed patient associated with dermatological manifestations suggestive of a more rare genetic disorder with cutaneous expression

Exclusion Criteria:

  • Mosaicism
  • Neurofibromatosis, all type
  • Tuberous sclerosis
  • Ichthyosis vulgaris
  • Suspicion of somatic impairment (giant nevus)

Sites / Locations

  • Hôpital Universitaire Des Enfants Rein FabiolaRecruiting

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Genodermatosis patients

Arm Description

Children between 0 to 18 years old with the presence of dermatological symptoms suggesting genodermatosis or presence of systemic symptoms in an undiagnosed patient associated with dermatological manifestations suggestive of a more rare genetic disorder with cutaneous expression

Outcomes

Primary Outcome Measures

Genetic diagnostic by mendeliome
Proportion of patients for whom a genetic diagnosis has been established using the mendeliome method. American College of Medical Genetics and Genomics. Diagnostic variants are classified as "pathogenic" or "probably pathogenic" variants.

Secondary Outcome Measures

Genetic diagnostic by genome
Proportion of patients for whom a genetic diagnosis has been established using the genome method. American College of Medical Genetics and Genomics. Diagnostic variants are classified as "pathogenic" or "probably pathogenic" variants.
Genetic diagnostic by fibroblast transcriptome
Proportion of patients for whom a genetic diagnosis has been established using the fibroblast transcriptome method. American College of Medical Genetics and Genomics. Diagnostic variants are classified as "pathogenic" or "probably pathogenic" variants.
Relevance of dermatological symptoms
Correlation between dermatological signs and symptoms and a genetic diagnosis established by the mendelioma, genome and transcriptome method

Full Information

First Posted
March 11, 2019
Last Updated
April 11, 2019
Sponsor
Queen Fabiola Children's University Hospital
Collaborators
Center of Human Genetics - ULB in Brussels, Interuniversity Institute of Bioinformatics in Brussels
search

1. Study Identification

Unique Protocol Identification Number
NCT03873285
Brief Title
Method of Genetic Analysis in Genodermatoses
Acronym
GENODERM
Official Title
Development of a Genetic Analysis Method by Mendeliomes and Genomes in the Diagnosis of Genodermatoses and Rare Genetic Diseases With Cutaneous Expression
Study Type
Interventional

2. Study Status

Record Verification Date
March 2019
Overall Recruitment Status
Unknown status
Study Start Date
November 27, 2018 (Actual)
Primary Completion Date
November 2021 (Anticipated)
Study Completion Date
November 2021 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Queen Fabiola Children's University Hospital
Collaborators
Center of Human Genetics - ULB in Brussels, Interuniversity Institute of Bioinformatics in Brussels

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The goal of the study is to develop a method of genetic diagnosis in two stages, by mendelioma then by genome and transcriptome on fibroblast culture, in genodermatoses and rare diseases with cutaneous expression in the child.
Detailed Description
Interventional multicenter prospective study. Patients will be examined by a dermatologist to describe and identify the various skin lesions Collaboration with the geneticist team: clinical examination for relevant cases Patient records will be consulted. Relevant medical information, biological examinations and other complementary examinations will be studied. A blood sample (10 ml in EDTA tube) will be collected from the patient and his/her parents to store DNA for mediome and genome. A written parental and child consent (if age-appropriate) will be obtained and a study information sheet will be signed. They will also sign the usual genetic consent request for mendeliome, genome and transcriptome on culture of fibroblasts. A 4 mm punch skin biopsy (healthy or damaged depending on phenotype and indication) will be performed according to the standard technique. The fibroblast culture will be performed routinely by the Genetics Center Transcriptome will be done according to the processes set up at the Genetics Center Mendeliome analysis Allow the analysis of 4000 rare disease genes Will be performed according to routine analyzes of the genetics lab Uses the Highlander tools (web) Use of de novo filters, autosomal recessive, heterozygous compound, X linked, strong variant (LOF and canonical splice sites) Use of rarer filters: exomic or gene deletion, splicing (+/- 12 base pairs around exons) In unexplained severe cases, a genome supplemented with the 10Xgenomics method and a transcriptome of fibroblasts will be realized. This double strategy afford to get a genome of high interpretative quality. Genome analysis by the 10Xgenomics method (https://www.10xgenomics.com ) This method allows us to deconvolate haplotypes and allows the analysis of 16,000 other complementary genes and to obtain precisely defined structural variants. The transcriptome will better assess the genomic effects on gene expression. The genome and transcriptome will also assess the presence of deep intron mutations and their effect on splicing, and will be a sustainable resource for other long-term projects (analysis of non-coding regions, microRNAs, etc.)

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Genodermatosis, Rare Genetic Disease With Cutaneous Expression
Keywords
Genodermatosis, genetic, children

7. Study Design

Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
100 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Genodermatosis patients
Arm Type
Experimental
Arm Description
Children between 0 to 18 years old with the presence of dermatological symptoms suggesting genodermatosis or presence of systemic symptoms in an undiagnosed patient associated with dermatological manifestations suggestive of a more rare genetic disorder with cutaneous expression
Intervention Type
Genetic
Intervention Name(s)
Genetic diagnostic by mendeliome or genome
Intervention Description
For cases not explained by a mendeliomes: genome and transcriptome on fibroblast culture
Primary Outcome Measure Information:
Title
Genetic diagnostic by mendeliome
Description
Proportion of patients for whom a genetic diagnosis has been established using the mendeliome method. American College of Medical Genetics and Genomics. Diagnostic variants are classified as "pathogenic" or "probably pathogenic" variants.
Time Frame
At time of clinical diagnosis of genodermatosis
Secondary Outcome Measure Information:
Title
Genetic diagnostic by genome
Description
Proportion of patients for whom a genetic diagnosis has been established using the genome method. American College of Medical Genetics and Genomics. Diagnostic variants are classified as "pathogenic" or "probably pathogenic" variants.
Time Frame
At time of clinical diagnosis of genodermatosis
Title
Genetic diagnostic by fibroblast transcriptome
Description
Proportion of patients for whom a genetic diagnosis has been established using the fibroblast transcriptome method. American College of Medical Genetics and Genomics. Diagnostic variants are classified as "pathogenic" or "probably pathogenic" variants.
Time Frame
At time of clinical diagnosis of genodermatosis
Title
Relevance of dermatological symptoms
Description
Correlation between dermatological signs and symptoms and a genetic diagnosis established by the mendelioma, genome and transcriptome method
Time Frame
At time of clinical diagnosis of genodermatosis

10. Eligibility

Sex
All
Maximum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Children between 0 to 18 years old Presence of dermatological symptoms suggesting genodermatosis Presence of systemic symptoms in an undiagnosed patient associated with dermatological manifestations suggestive of a more rare genetic disorder with cutaneous expression Exclusion Criteria: Mosaicism Neurofibromatosis, all type Tuberous sclerosis Ichthyosis vulgaris Suspicion of somatic impairment (giant nevus)
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Deborah Salik, MD
Phone
0032 2 477 31 20
Email
Deborah.salik@huderf.be
First Name & Middle Initial & Last Name or Official Title & Degree
Guillaume Smits, MD PhD
Email
Guillaume.smits@erasme.ulb.ac.be
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Deborah Salik, MD
Organizational Affiliation
Hôpital Universitaire Des Enfants Rein Fabiola
Official's Role
Principal Investigator
Facility Information:
Facility Name
Hôpital Universitaire Des Enfants Rein Fabiola
City
Brussels
ZIP/Postal Code
1020
Country
Belgium
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Deborah Salik, MD
Phone
0032 2 477 31 20
Email
Deborah.salik@huderf.be
First Name & Middle Initial & Last Name & Degree
Deborah Salik, MD

12. IPD Sharing Statement

Learn more about this trial

Method of Genetic Analysis in Genodermatoses

We'll reach out to this number within 24 hrs